A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 51 sites in Germany. Open to participants aged 56 Days to 112 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-08.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given concomitantly with Infanrix hexa at 2, 3, 4, months (infant series) and at 11-12 months of age (toddler dose) in Germany.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
13-valent pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine
7-valent pneumococcal conjugate vaccine
Biological: 7-valent pneumococcal conjugate vaccine
Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Percentage of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after 3-dose infant series (5 months of age)
Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.
Time frame: One month after 3-dose infant series (5 months of age)
Percentage of Participants Achieving Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series.
Percentage of Participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after 3-dose infant series (5 months of age)
Geometric Mean Antibody Titer in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after 3-dose infant series (5 months of age)
Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
Predefined Antibody Levels for Haemophilus Influenzae Type b (0.15 µg/mL or 1.0 µg/mL), for Diphtheria Toxoid (0.01 or 0.1 International units \[IU\]/mL) and for Hepatitis B (≥ 10.0 mIU/mL).
Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose
Antibody concentration/geometric mean concentration as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: Immediately before (12 months of age) and one month after the toddler dose (13 months of age)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod)(2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Day 1 through 4 after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Day 1 through 4 after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Day 1 through 4 after each dose
Participants were recruited in Germany from October 2006 to April 2007.
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 301 | 303 |
| Vaccinated dose 1 | 300 | 303 |
| Vaccinated dose 2 | 296 | 297 |
| Vaccinated dose 3 | 294 | 293 |
| Completed | 293 | 293 |
| Not completed | 8 | 10 |
| Withdrew: Protocol violation | 3 | 4 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Failure to return | 1 | 0 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 293 | 293 |
| Completed | 290 | 287 |
| Not completed | 3 | 6 |
| Withdrew: Parent/legal guardian request | 1 | 1 |
| Withdrew: Failed to return | 0 | 1 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 290 | 287 |
| Completed | 289 | 286 |
| Not completed | 1 | 1 |
| Withdrew: Failed to return | 1 | 0 |
| Withdrew: Parent/legal guardian request | 0 | 1 |
Percentage of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| Percentage of Participants | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes-Serotype 4 | 98.2 (96.0 to 99.4) | 98.2 (95.9 to 99.4) |
| Common Serotypes-Serotype 6B | 77.5 (72.2 to 82.2) | 87.1 (82.5 to 90.8) |
| Common Serotypes-Serotype 9V | 98.6 (96.4 to 99.6) | 96.4 (93.5 to 98.3) |
| Common Serotypes-Serotype 14 | 98.9 (96.9 to 99.8) | 97.5 (94.9 to 99.0) |
| Common Serotypes-Serotype 18C | 97.2 (94.5 to 98.8) | 98.6 (96.3 to 99.6) |
| Common Serotypes-Serotype 19F | 95.8 (92.7 to 97.8) | 96.0 (93.0 to 98.0) |
| Common Serotypes-Serotype 23F | 88.7 (84.5 to 92.2) | 89.5 (85.3 to 92.9) |
| Additional Serotypes-Serotype 1 | 96.1 (93.2 to 98.1) | 1.4 (0.4 to 3.7) |
| Additional Serotypes-Serotype 3 | 98.2 (95.9 to 99.4) | 6.3 (3.7 to 9.8) |
| Additional Serotypes-Serotype 5 | 93.0 (89.3 to 95.6) | 31.6 (25.8 to 37.8) |
| Additional Serotypes-Serotype 6A | 91.9 (88.1 to 94.8) | 31.6 (26.1 to 37.5) |
| Additional Serotypes-Serotype 7F | 98.6 (96.4 to 99.6) | 4.0 (2.0 to 7.0) |
| Additional Serotypes-Serotype 19A | 99.3 (97.5 to 99.9) | 79.2 (73.8 to 83.9) |
Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.
| μg/mL | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 | 2.18 (1.98 to 2.40) | 2.99 (2.68 to 3.33) |
| Common Serotypes - Serotype 6B | 0.98 (0.84 to 1.14) | 1.49 (1.27 to 1.75) |
| Common Serotypes - Serotype 9V | 1.65 (1.51 to 1.80) | 1.96 (1.77 to 2.17) |
| Common Serotypes - Serotype 14 | 4.14 (3.68 to 4.66) | 4.61 (4.07 to 5.23) |
| Common Serotypes - Serotype 18C | 1.94 (1.76 to 2.14) | 2.25 (2.04 to 2.49) |
| Common Serotypes - Serotype 19F | 1.73 (1.56 to 1.92) | 2.86 (2.53 to 3.24) |
| Common Serotypes - Serotype 23F | 1.26 (1.11 to 1.43) | 1.44 (1.25 to 1.65) |
| Additional Serotypes - Serotype 1 | 1.83 (1.64 to 2.04) | 0.03 (0.02 to 0.03) |
| Additional Serotypes - Serotype 3 | 1.55 (1.41 to 1.72) | 0.05 (0.04 to 0.06) |
| Additional Serotypes - Serotype 5 | 1.31 (1.17 to 1.46) | 0.20 (0.18 to 0.23) |
| Additional Serotypes - Serotype 6A | 1.33 (1.18 to 1.49) | 0.23 (0.20 to 0.26) |
| Additional Serotypes - Serotype 7F | 2.59 (2.36 to 2.85) | 0.04 (0.04 to 0.05) |
| Additional Serotypes - Serotype 19A | 3.26 (2.97 to 3.59) | 0.64 (0.58 to 0.71) |
Percentage of Participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| Percentage of Participants | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes - Serotype 4 (n=92,94) | 100.0 (96.1 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 6B (n=100,94) | 96.0 (90.1 to 98.9) | 98.9 (94.2 to 100.0) |
| Common Serotypes - Serotype 9V (n=89,89) | 100.0 (95.9 to 100.0) | 100.0 (95.9 to 100.0) |
| Common Serotypes - Serotype 14 (n=95,89) | 100.0 (96.2 to 100.0) | 100.0 (95.9 to 100.0) |
| Common Serotypes - Serotype 18C (n=100,94) | 100.0 (96.4 to 100.0) | 98.9 (94.2 to 100.0) |
| Common Serotypes - Serotype 19F (n=100,94) | 96.0 (90.1 to 98.9) | 93.6 (86.6 to 97.6) |
| Common Serotypes - Serotype 23F (n=100,93) | 96.0 (90.1 to 98.9) | 95.7 (89.4 to 98.8) |
| Additional Serotypes - Serotype 1 (n=100,92) | 93.0 (86.1 to 97.1) | 4.3 (1.2 to 10.8) |
| Additional Serotypes - Serotype 3 (n=100,94) | 99.0 (94.6 to 100.0) | 24.5 (16.2 to 34.4) |
| Additional Serotypes - Serotype 5 (n=100,94) | 99.0 (94.6 to 100.0) | 4.3 (1.2 to 10.5) |
| Additional Serotypes - Serotype 6A (n=99,93) | 96.0 (90.0 to 98.9) | 72.0 (61.8 to 80.9) |
| Additional Serotypes - Serotype 7F (n=99,94) | 100.0 (96.3 to 100.0) | 78.7 (69.1 to 86.5) |
| Additional Serotypes - Serotype 19A (n=95,94) | 100.00 (96.2 to 100.0) | 17.0 (10.1 to 26.2) |
Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| titer | 13vPnC | 7vPnC |
|---|---|---|
| Common Serotypes -Serotype 4 (n=92,94) | 1573.29 (1283.03 to 1929.21) | 1860.79 (1540.00 to 2248.41) |
| Common Serotypes - Serotype 6B (n=100,94) | 744.43 (556.91 to 995.11) | 1160.76 (921.46 to 1462.19) |
| Common Serotypes - Serotype 9V (n=89,89) | 4937.84 (3614.78 to 6745.14) | 5379.51 (3935.51 to 7353.34) |
| Common Serotypes - Serotype 14 (n=95,89) | 2139.65 (1570.10 to 2915.79) | 3345.19 (2473.27 to 4524.50) |
| Common Serotypes - Serotype 18C (n=100,94) | 1509.65 (1243.64 to 1832.56) | 1780.26 (1382.42 to 2292.59) |
| Common Serotypes - Serotype 19F (n=100,94) | 150.12 (116.89 to 192.81) | 165.69 (122.98 to 223.23) |
| Common Serotypes - Serotype 23F (n=100,93) | 1089.92 (795.20 to 1493.86) | 1070.83 (786.59 to 1457.78) |
| Additional Serotypes - Serotype 1 (n=100,92) | 50.21 (39.39 to 64.02) | 4.15 (3.99 to 4.32) |
| Additional Serotypes - Serotype 3 (n=100,94) | 250.73 (205.52 to 305.89) | 6.13 (5.17 to 7.28) |
| Additional Serotypes - Serotype 5 (n=100,94) | 162.02 (126.31 to 207.82) | 4.64 (3.96 to 5.43) |
| Additional Serotypes - Serotype 6A (n=99,93) | 1228.45 (883.49 to 1708.11) | 122.40 (74.09 to 202.21) |
| Additional Serotypes - Serotype 7F (n=99,94) | 11544.75 (9364.02 to 14233.34) | 115.45 (75.16 to 177.32) |
| Additional Serotypes - Serotype 19A (n=95,94) | 442.48 (360.53 to 543.06) | 6.70 (5.19 to 8.66) |
Predefined Antibody Levels for Haemophilus Influenzae Type b (0.15 µg/mL or 1.0 µg/mL), for Diphtheria Toxoid (0.01 or 0.1 International units \[IU\]/mL) and for Hepatitis B (≥ 10.0 mIU/mL).
| Percentage of Participants | 13vPnC After Infant Series | 7vPnC After Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Haemophilus influenzae type b 0.15 µg/mL threshold | 89.5 (85.2 to 92.9) | 86.9 (82.1 to 90.8) | 100.0 (98.5 to 100.0) | 100.0 (98.5 to 100.0) |
| Haemophilus influenzae type b 1.0 µg/mL threshold | 58.4 (52.3 to 64.4) | 54.0 (47.6 to 60.2) | 99.6 (97.8 to 100.0) | 97.9 (95.2 to 99.3) |
| Diphtheria toxoid at 0.01 IU/mL threshold | 100.0 (98.7 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) |
| Diphtheria toxoid at 0.1 IU/mL threshold | 89.7 (85.5 to 93.0) | 94.2 (90.6 to 96.7) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) |
| Hepatitis B at ≥ 10.0 mIU/mL | 94.9 (91.7 to 97.2) | 96.3 (93.2 to 98.2) | 99.3 (97.4 to 99.9) | 98.5 (96.1 to 99.6) |
| μg/mL | 13vPnC After Infant Series | 7vPnC After Infant Series | 13vPnC AfterToddler Dose | 7vPnC AfterToddler Dose |
|---|---|---|---|---|
| Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose | 1.23 (1.03 to 1.46) | 1.00 (0.83 to 1.20) | 11.79 (10.36 to 13.41) | 10.24 (8.88 to 11.82) |
| IU/mL | 13vPnC After Infant Series | 7vPnC After Infant Series | 13vPnC AfterToddler Dose | 7vPnC AfterToddler Dose |
|---|---|---|---|---|
| Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose | 0.36 (0.32 to 0.41) | 0.53 (0.47 to 0.60) | 2.67 (2.44 to 2.93) | 3.08 (2.74 to 3.47) |
Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| mIU/mL | 13vPnC After Infant Series | 7vPnC After Infant Series | 13vPnC AfterToddler Dose | 7vPnC AfterToddler Dose |
|---|---|---|---|---|
| Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose | 145.19 (122.62 to 171.92) | 165.25 (140.33 to 194.61) | 1118.05 (935.26 to 1336.56) | 1195.82 (976.12 to 1464.98) |
Antibody concentration/geometric mean concentration as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC Before Toddler Dose | 7vPnC Before Toddler Dose | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Common Serotypes -Serotype 4 (n=277,264,276,263) | 0.46 (0.42 to 0.51) | 0.58 (0.53 to 0.64) | 4.16 (3.75 to 4.62) | 5.07 (4.53 to 5.67) |
| Common Serotypes - Serotype 6B (n=275,261,273,251) | 0.97 (0.87 to 1.07) | 1.06 (0.94 to 1.20) | 9.14 (8.14 to 10.26) | 9.85 (8.66 to 11.22) |
| Common Serotypes - Serotype 9V (n=277,265,277,262) | 0.46 (0.42 to 0.50) | 0.52 (0.48 to 0.57) | 2.75 (2.52 to 2.99) | 3.36 (3.02 to 3.73) |
| Common Serotypes - Serotype 14 (n=273,263,276,260) | 2.20 (1.96 to 2.48) | 2.65 (2.34 to 3.00) | 8.34 (7.50 to 9.28) | 11.01 (9.87 to 12.29) |
| Common Serotypes-Serotype 18C (n=277,265,276,263) | 0.33 (0.30 to 0.36) | 0.39 (0.36 to 0.43) | 2.79 (2.53 to 3.07) | 3.44 (3.08 to 3.84) |
| Common Serotypes-Serotype 19F (n=276,264,276,263) | 0.68 (0.60 to 0.76) | 0.58 (0.52 to 0.66) | 5.99 (5.36 to 6.68) | 4.72 (4.12 to 5.41) |
| Common Serotypes-Serotype 23F (n=275,264,277,264) | 0.33 (0.30 to 0.37) | 0.39 (0.34 to 0.45) | 3.36 (2.98 to 3.78) | 4.33 (3.75 to 5.00) |
| Additional - Serotype 1 (n=277,264,278,257) | 0.52 (0.48 to 0.57) | 0.03 (0.02 to 0.03) | 4.25 (3.80 to 4.75) | 0.03 (0.03 to 0.04) |
| Additional - Serotype 3 (n=275,264,278,255) | 0.25 (0.23 to 0.28) | 0.05 (0.05 to 0.06) | 1.02 (0.92 to 1.13) | 0.07 (0.06 to 0.08) |
| Additional - Serotype 5 (n=275,264,276,220) | 0.74 (0.67 to 0.81) | 0.34 (0.30 to 0.39) | 3.56 (3.25 to 3.89) | 0.51 (0.45 to 0.58) |
| Additional - Serotype 6A (n=276,264,274,255) | 0.76 (0.68 to 0.85) | 0.33 (0.29 to 0.37) | 5.88 (5.24 to 6.59) | 1.74 (1.51 to 2.01) |
| Additional - Serotype 7F (n=277,264,278,263) | 0.99 (0.91 to 1.08) | 0.04 (0.04 to 0.04) | 4.79 (4.29 to 5.34) | 0.05 (0.04 to 0.05) |
| Additional - Serotype 19A (n=277,264,271,260) | 1.28 (1.14 to 1.45) | 0.72 (0.65 to 0.80) | 9.58 (8.68 to 10.58) | 3.79 (3.40 to 4.21) |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod)(2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Tenderness-Any (n=267,267,250,241,229,221,206,96) | 33.0 | 32.6 | 29.2 | 31.5 | 27.1 | 21.3 | 53.4 | 51.9 |
| Tenderness-Sig (n=260,258,236,226,215,209,176,158) | 7.7 | 7.0 | 4.7 | 7.5 | 4.2 | 2.9 | 10.8 | 12.7 |
| Swelling-Any (n=266,263,244,242,226,224,190,176) | 28.2 | 20.5 | 26.6 | 35.1 | 26.1 | 28.6 | 36.8 | 43.8 |
| Swelling-Mild (n=265,263,243,239,226,223,186,172) | 24.5 | 19.0 | 24.3 | 33.5 | 24.8 | 27.8 | 33.3 | 40.7 |
| Swelling-Mod (n=261,256,235,227,217,211,174,158) | 7.3 | 5.9 | 7.7 | 6.6 | 6.9 | 5.2 | 12.1 | 12.7 |
| Swelling-Severe(n=259,255,232,223,214,208,166,152) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Redness-Any (n=266,272,247,252,238,231,196,184) | 28.2 | 36.4 | 34.4 | 46.8 | 34.9 | 39.8 | 47.4 | 56.0 |
| Redness-Mild (n=265,271,247,250,237,229,191,180) | 27.2 | 36.2 | 33.6 | 45.6 | 34.2 | 38.9 | 44.5 | 52.8 |
| Redness-Mod (n=260,256,232,224,217,210,173,158) | 1.9 | 1.6 | 1.7 | 3.6 | 4.6 | 2.4 | 11.6 | 15.2 |
| Redness-Severe (n=259,255,232,222,214,208,166,153) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 |
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 |
|---|---|---|---|---|---|---|
| Fever ≥38°C but ≤ 39°C (n=269,266,248,250,242,232) | 43.5 | 38.7 | 46.8 | 48.4 | 46.3 | 36.6 |
| Fever >39°C but ≤40°C (n=260,256,238,225,216,210) | 4.2 | 1.6 | 8.8 | 4.4 | 3.7 | 1.4 |
| Fever >40°C (n=259,256,233,223,216,209) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Decreased Appetite (n=269,267,249,245,236,225) | 33.1 | 30.3 | 33.7 | 34.3 | 33.1 | 30.2 |
| Irritability (n=275,266,254,252,238,235) | 42.5 | 45.1 | 47.2 | 55.2 | 45.4 | 48.9 |
| Increased Sleep (n=284,272,258,256,240,241) | 61.6 | 58.8 | 53.9 | 66.8 | 49.6 | 49.4 |
| Decreased Sleep (n=266,264,240,234,230,221) | 25.2 | 26.1 | 23.8 | 23.1 | 20.9 | 24.4 |
| Meds to Prevent Sx (n=261,262,237,234,220,220) | 8.8 | 9.5 | 10.1 | 15.4 | 10.0 | 15.0 |
| Meds to Treat Sx (n=263,266,244,235,226,225) | 20.2 | 21.1 | 28.3 | 27.2 | 20.8 | 19.1 |
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|
| Fever ≥38°C but ≤ 39°C (n=206,200) | 58.7 | 62.0 |
| Fever >39°C but ≤40°C (n=174,157) | 12.6 | 8.9 |
| Fever >40°C (n=166,152) | 0.6 | 0.0 |
| Decreased Appetite (n=204,192) | 43.6 | 46.4 |
| Irritability (n=213,200) | 55.4 | 61.0 |
| Increased Sleep (n=202,197) | 56.4 | 54.8 |
| Decreased Sleep (n=195,170) | 31.8 | 28.8 |
| Medication to Prevent Symptoms (n=184,182) | 32.1 | 33.0 |
| Medication to Treat Symptoms (n=178,167) | 18.0 | 18.6 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 12/300 (4%) | 220/299 (73.6%) |
| 7vPnC Infant Series | — | 10/303 (3.3%) | 225/300 (75%) |
| 13vPnC Post-Infant Series | — | 21/300 (7%) | 13/299 (4.3%) |
| 7vPnC Post-Infant Series | — | 23/303 (7.6%) | 25/300 (8.3%) |
| 13vPnC Toddler Dose | — | 3/300 (1%) | 152/289 (52.6%) |
| 7vPnC Toddler Dose | — | 4/303 (1.3%) | 143/284 (50.4%) |
| 13vPnC 6-Month Follow-up | — | 11/300 (3.7%) | 11/287 (3.8%) |
| 7vPnC 6-Month Follow-up | — | 14/303 (4.6%) | 8/287 (2.8%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Dose | 7vPnC Toddler Dose | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| BronchitisInfections and infestations | 2/300 | 4/303 | 1/300 | 0/303 | 0/300 | 1/303 | 0/300 | 0/303 |
| GastroenteritisInfections and infestations | 1/300 | 0/303 | 1/300 | 4/303 | 1/300 | 1/303 | 3/300 | 3/303 |
| Gastroenteritis rotavirusInfections and infestations | 2/300 | 2/303 | 2/300 | 3/303 | 1/300 | 1/303 | 1/300 | 3/303 |
| Skeletal injuryInjury, poisoning and procedural complications | 0/300 | 0/303 | 2/300 | 3/303 | 0/300 | 0/303 | 0/300 | 2/303 |
| DehydrationMetabolism and nutrition disorders | 0/300 | 0/303 | 0/300 | 1/303 | 1/300 | 0/303 | 2/300 | 1/303 |
| Febrile convulsionNervous system disorders | 0/300 | 0/303 | 1/300 | 1/303 | 0/300 | 1/303 | 0/300 | 2/303 |
| PyelonephritisInfections and infestations | 0/300 | 0/303 | 0/300 | 2/303 | 0/300 | 0/303 | 0/300 | 0/303 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 0/300 | 2/303 | 0/300 | 0/303 | 0/300 | 0/303 | 0/300 | 0/303 |
| Accidental exposureInjury, poisoning and procedural complications | 0/300 | 0/303 | 1/300 | 0/303 | 0/300 | 0/303 | 0/300 | 0/303 |
| AcidosisMetabolism and nutrition disorders | 0/300 | 0/303 | 1/300 | 0/303 | 0/300 | 0/303 | 0/300 | 0/303 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Dose | 7vPnC Toddler Dose | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| Increased sleepGeneral disorders | 139/258 | 171/256 | — | — | — | — | — | — |
| Fever ≥38°C but ≤39°CGeneral disorders | 117/269 | 103/266 | — | — | 121/206 | 124/200 | — | — |
| Increased sleepGeneral disorders | 175/284 | 160/272 | — | — | 114/202 | 108/197 | — | — |
| IrritabilityGeneral disorders | 117/275 | 120/266 | — | — | 118/213 | 122/200 | — | — |
| Erythema (Any)Skin and subcutaneous tissue disorders | 75/266 | 99/272 | — | — | 93/196 | 103/184 | — | — |
| IrritabilityGeneral disorders | 120/254 | 139/252 | — | — | — | — | — | — |
| Tenderness (Any)Skin and subcutaneous tissue disorders | 88/267 | 87/267 | — | — | 110/206 | 96/185 | — | — |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 72/265 | 98/271 | — | — | 85/191 | 95/180 | — | — |
| Increased sleepGeneral disorders | 119/240 | 119/241 | — | — | — | — | — | — |
| IrritabilityGeneral disorders | 108/238 | 115/235 | — | — | — | — | — | — |
| Age Continuous(months) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.5 ± 0.6 | 2.5 ± 0.6 | 2.5 ± 0.6 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 151 | 127 | 278 |
| Male | 150 | 176 | 326 |
The record gives a start of Oct 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 4 years after primary completion. A results delay was requested in Feb 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →